PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA

Abstract

The aim of the study is to assess the economic feasibility of using pomalidomide in patients with recurrent and refractory multiple myeloma (MM), who had received previous 1st and 2nd (bortezomib and lenalidomide) line therapy.Materials and Methods. In this study, the methods of cost analysis, cost – effectiveness analysis, budget impact analysis (in relation to the State Guarantees Program) as well as sensitivity-toprice-change analysis were used.Results. The results indicate that the pomalidomide therapy in patients with recurrent and refractory MM who had previously received 1st and 2nd (bortezomib and lenalidomide) line therapy is clinically beneficial and also economically feasible in terms of public procurement. If introduced this program can save the Federal budget up to 232 785 963 rubles.Conclusion. According to the budget impact analysis, if pomalidomide (Innovid) is included in the list of public procurement, then the Federal spending on the treatment of MM with pomalidomide, lenalidomide and bortezomib will be less by 12% compared to the MM treatment with bortezomib and lenalidomide only.

Keywords

• pharmacoeconomics
• multiple myeloma
• refractory
• recurrent
• pomalidomide
• lenalidomide
• bortezomib